Posts by: Daniela Semedo

Daniela Semedo

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

May 18, 2017

First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma

News

The first patient has been enrolled in Targovax‘s pilot clinical trial for advanced or unresectable melanoma patients whose cancer progressed after treatment with checkpoint inhibitors. The study is being conducted at Memorial ... Read more

April 13, 2017

Combining IMO-2125 and Yervoy Shows Promise in Certain Metastatic Melanoma Patients

News

Combining Idera Pharmaceuticals‘ intratumoral IMO-2125 treatment with Yervoy (ipilimumab) may be a promising treatment approach for patients with metastatic melanoma who are refractory to anti-PD-1 therapies, according to preliminary data from ... Read more

March 23, 2017March 23, 2017

DecisionDx-Melanoma Test Shows Promise in Predicting Distant Metastasis

News

Castle Biosciences‘ DecisionDx-Melanoma gene expression profile (GEP) test is a promising tool to identify melanoma patients at high risk of developing metastatic disease, according to recently presented data from five studies ... Read more

March 21, 2017March 21, 2017

Advanced Melanoma Patients with Initial BRAF Therapy Resistance Can Be Treated Again, Study Finds

News

People with advanced and metastatic melanoma who had become resistant to BRAF-targeted therapy were successfully retreated with this therapy after a three-month pause, researchers in Belgium reported. A liquid biopsy tool, Idylla ... Read more

December 22, 2016

Partners Should Be Trained to Check for Mole Irregularities

News

A new study from Northwestern Medicine shows the advantages of partners frequently checking for potentially dangerous moles, after receiving training to do so. The study, “Self-confidence and Embarrassment About Partner-Assisted Skin ... Read more

November 1, 2016November 1, 2016

Promising Clinical Data from Melanoma Combination Therapy to Be Presented at Upcoming Meeting

News

Array BioPharma and Pierre Fabre will present data from the COLUMBUS Phase 3 clinical trial showing that melanoma patients with BRAF mutations may benefit more from the combination of encorafenib and ... Read more

September 15, 2016

Rapid Detection of Malignant Melanoma Mutation Now Possible Using Nanotechnology

News

A new nanotechnology method can easily and quickly detect genetic changes in tissue samples. The innovative method developed by researchers from the Swiss Nanoscience Institute at the University of Basel ... Read more

September 1, 2016September 1, 2016

Advanced Head and Neck Melanomas Often Found Where They’re Hardest to See

News

Advanced-stage cutaneous head and neck melanomas are diagnosed more often on the scalp or back of the neck than toward the front of the body, like the face or ears, according to a ... Read more

July 12, 2016July 12, 2016

Easier Access to Melanoma Screenings Doesn’t Result in Excessive Treatment, Community Study Reports

News

Results from a large-scale melanoma screening conducted in Pennsylvania indicate that, overall, the practice complies with the medical maxim: “first do no harm.” The numbers show that melanoma screenings did ... Read more

June 30, 2016June 30, 2016

Melanoma Skin Check Partners Help Patients Identify New Cancers

News

A recent clinical trial proved that skin-check partners of melanoma patients can successfully assist with skin self-examinations by recognizing new melanomas and increasing early detection of the cancer. The study, “Early Detection of New Melanomas ... Read more

June 16, 2016June 16, 2016

Early Studies Show Ricolinostat Boosts Immunotherapy Used to Treat Melanoma

News

Acetylon Pharmaceuticals announced the publication of two abstracts describing preclinical trials that demonstrated the potential of ricolinostat (ACY-1215), a HDAC6 inhibitor, to augment immunotherapies used to treat melanoma, and plans to start clinical testing in ... Read more

May 26, 2016May 26, 2016

EC Approves Immuno-Oncology Combination of Opdivo and Yervoy Regimen for Advanced Melanoma

News

The European Commission (EC) has approved  the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) in the treatment of patients diagnosed with BRAF V600 wild-type unresectable or metastatic melanoma. This is the first and only combination treatment of two ... Read more

May 25, 2016May 25, 2016

2 Metastatic Melanoma Patients Reported to Live Disease-free for Years After Immunotherapy

News

A case study reported on two patients with advanced melanoma that had spread to the liver, who experienced progression-free long-term survival — of 4.5 and 12 years — following removal of ... Read more

April 28, 2016April 28, 2016

Nivolumab (Opdivo) Seen in Clinical Trial to Improve Long-Term Survival in Advanced Melanoma Patients

News

Bristol-Myers Squibb’s nivolumab (Opdivo) has shown a robust five-year overall survival (OS) rate of 34 percent in heavily pretreated patients with metastatic melanoma, who had not received prior ipilimumab (Yervoy) therapy. The ... Read more

April 26, 2016April 26, 2016

Aging Influences Melanoma Response to Therapies, but Antioxidants Could Provide Answer

News

The risk of developing cancer increases with age as accumulated damage to the cells and chronic inflammation arise over time. In a new study published in Nature, an international team of ... Read more

April 5, 2016April 7, 2016

Advanced Melanoma Combo Treatment, Opdivo/Yervoy, Gets a Positive Opinion from CHMP

News

The Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion supporting the approval of Bristol-Myers Squibb‘s Opdivo (nivolumab), combined with Yervoy (ipilimumab), to treat adult patients with advanced (unresectable or metastatic) melanoma. The CHMP opinion also added a statement to ... Read more

March 31, 2016March 31, 2016

Immunocore Recruits 1st Uveal Melanoma Patient in Phase I Trial of Biological Drug, IMCgp100

News

Immunocore announced it has recruited the first patient for its Phase I monotherapy clinical trial of IMCgp100, its lead product candidate to treat uveal melanoma. Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, ... Read more

March 29, 2016March 29, 2016

Melanoma Study in Mice Uses a Microneedle Patch System to Effectively Deliver Immunotherapy

News

Despite advances in melanoma treatment, mainly as a consequence of anti-PD-1 (aPD1) immunotherapy, the approach still needs improvement. Now, North Carolina State University and the University of North Carolina at Chapel Hill ... Read more

March 17, 2016March 17, 2016

myPath Melanoma Test Shows 90% Accuracy in 2nd Trial, Company Reports at USCAP 2016

News

Myriad Genetics, Inc., recently released positive data from a second and pivotal clinical validation trial of its myPath Melanoma test in a poster presentation at the 2016 USCAP Annual Meeting in Seattle, Washington. “There is significant emotional distress associated ... Read more

March 3, 2016March 3, 2016

Melanomas Often Diagnosed in People with a Limited Number of Skin Moles, Study Reports

News

Nevi, or skin moles, are strongly associated with melanoma. But recent findings revealed that most melanoma patients have few and no atypical moles, and thick melanomas in people under age 60 are more often found in ... Read more